Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-label, Blinded Primary Endpoint, Randomized Multicenter Trial to Assess the Effectiveness of Evolocumab With Routine Lipid Management Compared With Routine Lipid Management Alone in Reducing the Plaque Burden in Patients With Subclinical Atheroma

NCT07803679 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07803679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07803679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-label, Blinded Primary Endpoint, Randomized Multicenter Trial to Assess the Effectiveness of Evolocumab With Routine Lipid Management Compared With Routine Lipid Management Alone in Reducing the Plaque Burden in Patients With Subclinical Atheroma
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
April 30, 2029
Enrollment
308 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atheroma, atherosclerotic plaque, coronary artery disease, hypercholesterolemia